Introduction 

Antibody‑based therapeutics have evolved dramatically over the past decades, transforming cancer treatment by harnessing the specificity of antibodies for tumor‑associated antigens, recruiting immune effector functions, or delivering payloads. Nevertheless, limitations remain: antigen escape, on‑target off‑tumor toxicity, sub‑optimal biodistribution, and immunosuppressive tumor microenvironments. Recently, there has been a surge of molecular innovations in antibody‑based strategies including:

• biparatopic antibodies (bind two epitopes on the same antigen)
• advances in antibody‑drug conjugates
• improved conditionally active antibodies
• molecular engineering of Fc domains
• antibody‑oligonucleotide conjugates
• antibody cytokine fusions (immunocytokines)

These new designs aim not just to refine the older monoclonal‑antibody formats, but to expand the reach of antibody therapeutics into novel mechanisms of action, improved safety, and greater tumor selectivity. In this article we review key molecular advances, describe their background, and dive into what each advancement brings to cancer therapy.

Biparatopic  Antibodies

Bispecific antibodies combine two antigen‑binding regions in one molecule and can simultaneously engage two tumor/immune targets, redirect immune effector cells to tumor cells, or block two signaling pathways.  Multiple new bispecific formats have entered the clinic or advanced pre‑clinically. These include improved modular scaffolds, optimized pharmacokinetics, enhanced safety profiles (reduced cytokine release), and refined specificity (co‑targeting of tumor antigen + immune cell receptor).

A biparatopic antibody combines two distinct antigen-binding sites (paratopes), each recognizing a different epitope on a single target antigen.   A striking example is zanidatamab, a biparatopic antibody which was approved by the U.S. FDA in November 2024 for unresectable or metastatic HER2‑positive biliary tract cancer. 

Zanidatamab targets two distinct non-overlapping epitopes on the HER2 receptor, enabling simultaneous binding that promotes receptor clustering, internalization, and degradation (1). This dual engagement effectively blocks both ligand-dependent and ligand-independent HER2 dimerization with other ErbB family members, leading to inhibition of downstream intracellular signaling pathways, reduced tumor cell proliferation, and enhanced apoptosis. Additionally, zanidatamab retains an intact IgG1 Fc region, which mediates immune effector functions such as antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis, contributing to tumor cell killing. Its unique biparatopic mechanism provides synergistic signaling inhibition and potent anti-tumor activity. It is currently being developed for the treatment of HER2-positive malignancies including biliary tract (approved by the FDA), gastric, and breast cancers.

Next‑Generation Antibody‑Drug Conjugates (ADC)

An antibody-drug conjugate (ADC) is a targeted cancer therapy that combines a monoclonal antibody with a potent cytotoxic drug attached via a chemical linker. The antibody specifically binds to a tumor-associated antigen, directing the cytotoxic payload to cancer cells while sparing most normal tissues. Upon internalization into the cancer cell, the linker is cleaved, releasing the drug to induce cell death. ADC therapy has matured significantly, but challenges remain.  Hurdles to overcome include:  how to deliver potent payloads to tumor cells while sparing normal tissue, and how to overcome antigen heterogeneity and payload resistance.

Recent molecular innovations in ADCs:

• Novel payload classes with different modes (e.g., DNA damage, topoisomerase inhibitors)
• Improved cleavable/linker chemistries (tumor microenvironment‑sensitive linkers, pH/enzymatic triggers) that increase tumor specificity
• Site‑specific conjugation (ensuring homogeneous drug to antibody ratio, and better PK/PD)
• Optimization for “low‑antigen‑density” tumors (e.g., HER2‑low).

Modern ADCs integrate potent, mechanistically diverse payloads, micro-environment-responsive linkers, site-defined conjugation chemistries, and designs optimized for heterogeneous antigen expression. Collectively, these molecular changes transform ADCs from narrow, single-target cytotoxic drugs into precision medicines capable of treating a broader range of tumor phenotypes with improved safety and efficacy.

Table 1. Molecular Innovations in ADCs

**The bystander effect in cancer therapy is when a drug designed to kill targeted tumor cells also damages nearby, non-targeted cells. It happens when toxic molecules released from a targeted cell diffuse into surrounding cells. This enhances the overall tumor-killing efficiency, especially in heterogeneous tumors. However, it can also increase local toxicity if healthy cells are affected.

Conditionally‑Active Antibodies

A “conditionally active” antibody is engineered so that its binding or activity is suppressed (or “masked”) in normal healthy tissues but restored (activated) selectively in the disease/tumor microenvironment (TME). The motivation is to widen the therapeutic window by reducing on‑target/off‑tumor binding, thereby lowering systemic toxicity while maintaining effective target engagement within the tumor.

Key mechanistic features include:

• A masking moiety (peptide or domain) fused to the antibody, which sterically or allosterically blocks antigen binding until the mask is removed (e.g., by tumor‐associated proteases).
• A cleavable spacer that is sensitive to proteases enriched in the TME (e.g., matrix metalloproteinases, cathepsins) or other tumor‐specific triggers.
• In some designs, pH‑sensitive binding variants are used.  The masking peptide is removed in a pH-dependent manner. Binding is weak at physiological pH (~7.4), but stronger at acidic pH (e.g., ~6.5 or lower) typical of the TME.
• The “mask” enables spatial control of activity: high binding/effector function in tumor, minimal binding in healthy tissue.

Table 2. Molecular Advances in Conditionally Active Antibodies

Advanced Fc Engineering for Antibody Half‑Life and Effector Function Fine Tuning

Recently, significant progress has been made in engineering the Fc region (Fc receptor binding region) of antibodies to improve the efficacy, pharmacokinetics, and safety of antibody-based therapeutics. One major area of advancement involves extending antibody serum half-life through precise modulation of the interaction with the neonatal Fc receptor (FcRn). The neonatal Fc receptor (FcRn) is a pH-dependent receptor that binds to the Fc region of IgG antibodies. The Fc region naturally binds FcRn at acidic endosomal pH, allowing antibodies to avoid lysosomal degradation and be recycled back into circulation. By recycling these molecules back to the cell surface and releasing them at neutral pH, FcRn extends their serum half-life. This receptor plays a critical role in maintaining IgG homeostasis.  Recent studies have demonstrated that fine-tuning the kinetics of this interaction, rather than simply increasing equilibrium affinity, can dramatically enhance half-life (3). For example, variants increase binding at acidic pH while ensuring rapid release at neutral pH. In preclinical models, these variants exhibited up to a six-fold increase in serum half-life, while retaining complement-mediated cytotoxicity and favorable physicochemical properties.

In parallel, efforts have focused on enhancing antibody effector functions such as antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity. These functions depend on Fc interactions with Fc gamma receptors (FcγRs) on immune effector cells and with complement proteins. Recent molecular strategies include targeted point mutations within the Fc hinge and CH2 domains to selectively increase ADCC potency. Comparative studies have systematically evaluated panels of Fc mutations, demonstrating that precise modifications can enhance immune engagement without altering antigen binding or compromising stability (4). These developments are increasingly favoring mutational approaches over glycoengineering alone, which can be more complex to implement in manufacturing while still achieving significant improvements in effector function.

Another area of molecular innovation involves silencing Fc effector functions to reduce potential safety risks in therapeutic contexts where immune activation is undesirable. This approach is particularly relevant for agonist antibodies, checkpoint inhibitors, and Fc-fusion proteins, where unintended engagement of FcγRs or complement could trigger off-target cell killing or excessive inflammatory responses. Recent Fc variants incorporating mutations effectively eliminate detectable binding to FcγRs and complement protein C1q,

while preserving FcRn-mediated recycling and overall stability. These silenced Fc constructs allow antibodies to retain antigen binding and pharmacokinetic benefits while minimizing immune effector activity, providing a safer therapeutic profile in contexts where effector function is not required.

Collectively, these molecular advances demonstrate a sophisticated understanding of the Fc region’s role in antibody therapeutics, moving beyond simple affinity improvements to finely tuned control over half-life, effector activity, and safety, with broad applicability across multiple therapeutic modalities.

Antibody-Oligonucleotide Conjugates (AOCs)

An antibody‑oligonucleotide conjugate (AOC) is a chimeric molecule that links a monoclonal antibody (mAb) that recognizes a specific cell surface receptor with an oligonucleotide payload (for example, a small interfering RNA (siRNA), or antisense oligonucleotide (ASO).

In an AOC, the antibody first binds a specific cell-surface receptor that is highly expressed on target cells, leading to receptor-mediated endocytosis of the conjugate. Once internalized, the AOC is trafficked into endosomes where the acidic environment or specific enzymatic conditions promote cleavage of the linker between the antibody and oligonucleotide. This cleavage releases the oligonucleotide cargo within the endosomal compartment. The oligonucleotide then escapes from the endosome into the cytoplasm (or nucleus, depending on its design), where it engages its RNA or DNA target to modulate gene expression or splicing.

Recent advances in AOCs have focused on improving stability, delivery, efficacy, and predictability of these hybrid molecules. One key area has been the optimization of oligonucleotide chemistry.  These chemical improvements increase resistance to nuclease degradation, enhance potency in gene knock-down, and reduce immunogenicity, which together improve the in vivo stability and performance of the oligonucleotide payload once delivered by the antibody.

Another important advance is site-specific and homogeneous conjugation chemistry. Rather than attaching oligonucleotides randomly to lysine or cysteine residues, modern approaches use engineered cysteines, glycan engineering, or enzymatic methods such as microbial transglutaminase to control the precise site and number of conjugations per antibody. This ensures a defined drug-to-antibody ratio, preserves antibody binding, reduces batch-to-batch variability, and improves pharmacokinetics and pharmacodynamics, making AOCs more predictable and effective.

Linker design and internalization optimization have also been critical. The linkers connecting the antibody and oligonucleotide can be cleavable or non-cleavable, and their design influences whether the oligonucleotide is efficiently released in the cytosol or nucleus after cellular uptake. Optimizing the stability of the linker and the internalization pathway of the antibody has significantly improved intracellular delivery of the oligonucleotide, which is essential for gene-modulating activity.

Preclinical translation and structure-activity relationship studies have provided critical insights. Demonstrating robust mRNA knock-down in both small and large animal models confirms that these molecules can function effectively in vivo. Moreover, understanding how factors such as conjugation site, drug-antibody ratio, oligonucleotide chemistry, and antibody isotype influence pharmacokinetics, tissue distribution, and efficacy allows rational design and optimization of next-generation AOCs.

Overall, these molecular and technological advances have collectively enhanced the stability, targeting, intracellular delivery, predictability, and translational readiness of AOCs, significantly improving their potential as therapeutic agents for previously difficult-to-treat diseases.

Antibody‑Cytokine Fusions (Immunocytokines)

Antibody-cytokine fusions, particularly the next-generation masked immunocytokines, leverage precise molecular engineering to optimize both targeting and immune activation while minimizing systemic toxicity. These constructs consist of a cytokine (e.g., IL-2, IL-12, IL-15, or TNF)  fused to an antibody or antibody fragment that recognizes a tumor- or disease-specific antigen, ensuring selective tissue localization.

For example, an immunocytokine composed of an anti-PD-1 antibody fused to an IL-15/IL-15Rα complex promotes potent antitumor immune activation through synergistic molecular and cellular mechanisms (5). The anti-PD-1 antibody blocks the inhibitory PD-1/PD-L1 interaction on exhausted T cells, restoring their cytotoxic function, while the IL-15/IL-15Rα complex delivers localized cytokine signaling that enhances proliferation and survival of CD8⁺ effector T cells and NK cells. The fusion ensures co-targeting of IL-15 activity to the PD-1⁺ tumor-infiltrating lymphocytes within the tumor microenvironment, minimizing systemic cytokine toxicity. The combined effects result in increased infiltration, activation, and persistence of cytotoxic lymphocytes, leading to immunogenic destruction of tumor cells and progressive tumor size reduction.

For enhanced tumor selectivity over normal tissues, the cytokine is typically masked through a steric or peptide-based inhibitory domain linked via a protease-sensitive linker, rendering it inactive during systemic circulation. Within the tumor microenvironment, overexpressed proteases such as matrix metalloproteinases or cathepsins cleave the linker, releasing the mask and activating the cytokine in situ. This spatially restricted activation not only enhances local immune stimulation of T cells, NK cells, and dendritic cells but also reduces engagement of regulatory T cells and other off-target immune subsets, thereby improving the therapeutic index.

Conclusion

Antibody-based therapeutics continue to redefine the frontiers of cancer treatment through precise molecular engineering and integration of complementary biological functions. The emergence of biparatopic and conditionally active antibodies, next-generation ADCs with optimized linkers and payloads, Fc domain reprogramming, antibody-oligonucleotide conjugates, and immune-cytokine fusion technologies exemplify a new era of design sophistication. These innovations collectively address historical challenges, enhancing tumor specificity, overcoming immunosuppressive microenvironments, and minimizing systemic toxicity, while opening avenues for synergistic and personalized therapies. As the field moves forward, continued convergence of structural biology, synthetic biology, and immune-engineering will likely yield even more adaptable and potent antibody platforms, driving oncology closer to durable, mechanism-guided cures.

Table 3. Noteworthy antibody-cytokine fusion candidates that recently entered into clinical or advanced preclinical development.

References

1. Weisser, N. E., Wickman, G., Abraham, L., et al. “An anti-HER2 biparatopic antibody that induces unique and multiple mechanisms of action in HER2-expressing tumors.” Nature Communications, 14: 37029 (2023). DOI:10.1038/s41467-023-37029-3.

2. Boustany LM, LaPorte SL, Wong L, White C, Vinod V, Shen J, Yu W, Koditek D, Winter MB, Moore SJ, Mei L, Diep L, Huang Y, Liu S, Vasiljeva O, West J, Richardson J, Irving B, Belvin M, Kavanaugh WM. A Probody T Cell–Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity. Cancer Res. 2022 Nov 15;82(22):4288–4298. doi:10.1158/0008-5472.CAN-21-2483.

3. Foss S., Sakya S. A., Aguinagalde L., Lustig M., Shaughnessy J., Cruz A. R., … Andersen J. T. (2024). Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria. Nature Communications, 15, Article 2007. doi:10.1038/s41467-024-46321-9.

4. Hale G., Davy A.D., Wilkinson I., Sandra K. Systematic analysis of Fc mutations designed to enhance binding to Fc-gamma receptors. 2024;16(1):2406539. doi:10.1080/19420862.2024.2406539. PubMed PMID: 39306747; PMCID: PMC11418285.

5. Novel PD-1-targeted, activity-optimized IL-15 mutein SOT201 acting in cis provides antitumor activity superior to PD1-IL2v. J Immunother Cancer. 2025; (article). doi:10.1136/jitc-2024-010736. PMCID: PMC12007054.